While there are a range of existing treatments for different forms of cancer, they require continuous refinement to target the disease accurately and effectively. Additionally, there are many types of cancer that are yet to be addressed through drug therapy.
Our researchers are pioneering improvements and development of drug therapies directed by the latest disease research into cancer, and deep collaboration in shared areas of expertise.
Glioblastoma is a fatal brain tumour with no effective therapy. Professor Lenka Munoz and her team have discovered a novel class of chemotherapeutic agents that shows excellent blood brain barrier permeability and anti-cancer efficacy in aggressive xenograft models of glioblastoma.
Research is based around a second-generation Herpes Simplex Virus-1- based oncolytic vector designed to activate necroptosis in human cells to drive systemic anti-tumour immunity and provide a new therapeutic option for use in colorectal cancer.
Osteosarcomas are the most common type of paediatric bone cancers and often associated with harsh treatment options and low survival rates. Structure-based design is used to develop drug-like and cell-permeable peptidomimetic inhibitors for treating osteosarcomas.
Triple Negative Breast Cancer (TNBC) is the most aggressive subtype of breast cancer with a high rate of metastasis and relapse and a low survival rate. The mainstay treatment is general chemotherapy with low efficacy and severe side effects.
A novel peptide-based targeting strategy is being employed to develop a first-in-class radiotheranostic agent for TNBC.
